Milton Werner
Founder at INHIBIKASE THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
Milton Werner active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director/Board Member | 2008-08-31 | - |
| Chief Executive Officer | 2008-08-31 | - | |
| Founder | 2008-08-31 | - | |
| President | 2008-08-31 | - | |
| Investor Relations Contact | 2008-08-31 | - | |
| Winship Cancer Institute | Corporate Officer/Principal | - | - |
Career history of Milton Werner
Former positions of Milton Werner
| Companies | Position | Start | End |
|---|---|---|---|
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Chief Tech/Sci/R&D Officer | 2007-04-30 | 2007-07-31 |
| The Rockefeller University | Corporate Officer/Principal | 1996-08-31 | 2007-05-31 |
Training of Milton Werner
| University of Southern California | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Winship Cancer Institute |
- Stock Market
- Insiders
- Milton Werner
- Experience
